Analysed CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) News Sources
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
17-02-2026
yahoo.com
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
04-02-2026
yahoo.com
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
07-01-2026
yahoo.com
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
17-12-2025
yahoo.com
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
05-11-2025
yahoo.com
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
04-11-2025
yahoo.com
What is the current price of CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ)?
The current price of CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) is $0.0305.
CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) absolute price change since previous trading day?
The absolute price change of CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) since the previous trading day is $-0.003.
CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) percentage price change since previous trading day?
The percentage price change of CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) since the previous trading day is -8.9552%.
What is the most recent average sentiment score for CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ)?
The most recent average sentiment score for CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ)?
The most recent sentiment for CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ) is .
SEC-8K** Filing Available For CERO THERAPEUTICS HOLDINGS I (CERO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.